Trial Profile
An Exploratory, Prospective Phase II Study to Investigate Progression-Free Survival, Response and Overall Survival Seen With Pemetrexed/Cisplatin and the Role of Thymidylate Synthase Expression.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 18 Apr 2012 Planned number of patients changed from 60 to 68 as reported by European Clinical Trials Database record.
- 29 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.